# Boston Scientific to acquire NxThera for up to $406M

Boston Scientific has entered a definitive agreement to acquire NxThera, a privately-held company that developed the Rezūm system for treating benign prostatic hyperplasia. The deal includes an upfront cash payment of $306 million and up to $100 million in milestone payments.

- Type: Acquisition
- Announced: 2018-03-21
- Where: Maple Grove, Minnesota, United States
- Value: $306.0M
- Status: announced
- Products: Rezūm system (minimally invasive therapy for BPH)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Boston Scientific](https://endata.com/companies/15966.md) (acquirer)
- [NxThera](https://endata.com/companies/30864.md) (target)
- [nVision Medical Corporation](https://endata.com/companies/31344.md) (target)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-nxthera-300617391.html), 2018-03-21: "Boston Scientific today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota."
- [news.bostonscientific.com](https://news.bostonscientific.com/2018-04-16-Boston-Scientific-Announces-Acquisition-Of-nVision-Medical-Corporation), 2018-04-16: "Boston Scientific (NYSE: BSX) today announced that it has acquired nVision Medical Corporation, a privately-held company focused on women's health."
- [medicaldevice-network.com](https://www.medicaldevice-network.com/news/mas-week-air-liquide-flexan-boston-scientific/), 2018-04-19: "Boston Scientific has completed the acquisition of women’s health specialist company nVision Medical for $275m."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.